Correction to: Scientific Reports https://doi.org/10.1038/s41598-024-64260-9, published online 12 June 2024
The original version of this Article contained errors.
In the Results, under the subheading ‘Qualitative analysis’, ‘Long-covid studies’,
“A retrospective analysis of patients taking SSRIs at the time of infection showed a % reduction (p = 0.0004) in the relative risk of Long-covid among patients (n = 1521) receiving an SSRI with σ1R agonism (fluvoxamine, fluoxetine, escitalopram) and a 21% reduction (p = 0.005) in the relative risk of Long-covid among patients (n = 1803) taking an SSRI without σ1R agonism (citalopram, paroxetine, sertraline) compared with patients (n = 14,584) not taking an SSRI43. However, as pointed out by K. Hashimoto44 this study included citalopram as an SSRI with σ1R activity, which other studies have suggested as incorrect as it does not potentiate NGF-induced neurite outgrowth in PC-12 cells45.”
now reads:
“A retrospective analysis of patients taking SSRIs at the time of infection showed a 29% reduction (p = 0.0004) in the relative risk of Long-covid among patients (n = 1521) receiving an SSRI with σ1R agonism (fluvoxamine, fluoxetine, escitalopram) and a 21% reduction (p = 0.005) in the relative risk of Long-covid among patients (n = 1803) taking an SSRI without σ1R agonism (citalopram, paroxetine, sertraline) compared with patients (n = 14,584) not taking an SSRI43. As pointed out by K. Hashimoto,44 a preprint of this study included citalopram as an SSRI with σ1R activity, which other studies have suggested as incorrect as it does not potentiate NGF-induced neurite outgrowth in PC-12 cells45.”
Furthermore, Reference 43 contained an error and was incorrectly given as:
Sidky, H. et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. medRxiv (2022).
The correct reference is listed below:
Sidky, H. et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. Computational and Structural Biotechnology Journal 24, 115–125 (2024). https://doi.org/10.1016/j.csbj.2023.12.045
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Prasanth, M.I., Wannigama, D.L., Reiersen, A.M. et al. Author Correction: A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications. Sci Rep 14, 16774 (2024). https://doi.org/10.1038/s41598-024-67936-4
Published:
DOI: https://doi.org/10.1038/s41598-024-67936-4